Utama › Kegagalan Jantung › Missouri › Kansas City
Kajian klinikal Kegagalan Jantung di Kansas City, MO
25 kajian untuk Kegagalan Jantung sedang mencari peserta di lokasi dalam dan sekitar Kansas City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
ELEVATE-HFpEF Clinical Study
Mengambil peserta
- Saint Lukes Mid America Heart Institute, Kansas City
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Mengambil pesertaFasa 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Mengambil pesertaFasa 3
- Kansas City VA Medical Center, Kansas City
- North Kansas City Hospital, North Kansas City · 2 mi jauh
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Mengambil pesertaFasa 3
- Kansas City VA Medical Center, Kansas City
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Mengambil pesertaFasa 3
- Research Site, Kansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Mengambil pesertaFasa 3
- Saint Luke's Hospital of Kansas City, Kansas City
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Mengambil peserta
- Saint Luke's Hospital of Kansas City, Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Mengambil pesertaFasa 3
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Mengambil pesertaFasa 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Mengambil pesertaFasa 3
- Kansas City, MO Investigative Site 10002, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Mengambil pesertaFasa 3
- CON-10002 Kansas City, MO Investigative Site, Kansas City
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
Mengambil pesertaKajian pemerhatian
- St. Luke's Hospital of Kansas City, Kansas City
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Mengambil pesertaFasa 2
- Local Institution - 145, Kansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Mengambil pesertaKajian pemerhatian
- Kansas City, Kansas City
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Mengambil pesertaKajian pemerhatian
- St. Luke's Mid-America Heart Institute, Kansas City
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Mengambil pesertaFasa 3
- Tenax Investigational Site, Kansas City
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Mengambil pesertaFasa 3
- Clinical Research Consultants, JCCT Co, Kansas City
Assessment of CCM in HF With Higher Ejection Fraction
Mengambil peserta
- St. Lukes Hospital Kansas City (Mid America Heart Institute), Kansas City
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Mengambil pesertaFasa 3
- FIN-10002 Kansas City, MO Investigational Site, Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Mengambil peserta
- St. Lukes/ Mid-American Heart Institute, Kansas City
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Mengambil pesertaFasa 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Mengambil pesertaFasa 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Mengambil peserta
- St. Luke's Hospital, Kansas City
CCM OPEN HF Registry
Mengambil pesertaKajian pemerhatian
- Saint Luke's Hospital Mid America Heart Institute, Kansas City
- Saint Luke's Hospital of Kansas City, Kansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
Mengambil pesertaKajian pemerhatian
- Saint Luke's Health System, Kansas City
Kajian Kegagalan Jantung di bandar lain
- New York City, NY51 kajian
- Boston, MA44 kajian
- Dallas, TX42 kajian
- Houston, TX36 kajian
- Cleveland, OH33 kajian
- Chicago, IL31 kajian
- Philadelphia, PA31 kajian
- San Francisco, CA29 kajian
- Durham, NC26 kajian
- St. Louis, MO26 kajian
- Atlanta, GA25 kajian
- Cincinnati, OH24 kajian
Kajian lain di Kansas City
- Kanser Payudara34 kajian
- Kanser Paru-paru Bukan Sel Kecil31 kajian
- Kanser (semua jenis)21 kajian
- Kanser Paru-paru19 kajian
- Kanser Kolorektal16 kajian
- Kanser Metastatik15 kajian
- Leukemia Mieloid Akut15 kajian
- Kanser Prostat14 kajian
- Kanser Ovari11 kajian
- Obesiti11 kajian
- Diabetes Jenis 211 kajian
- Penyakit Kardiovaskular11 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.